- Sarepta Therapeutics (SRPT +4.9%) is on the move, and with today's gains the shares are up some 10% since Wednesday when disappointing dystrophin production data from Prosensa's (NASDAQ:RNA) drisapersen boosted sentiment around eteplirsen.
- Today's catalyst appears to be a note out of Piper which emphasizes eteplirsen's safety profile.
- SRPT is now up more than 50% since the end of August.
Sarepta rallies as Piper upbeat on eteplirsen NDA
Recommended For You
More Trending News
About SRPT Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
SRPT | - | - |
Sarepta Therapeutics, Inc. |